UNDERWRITING AGREEMENTUnderwriting Agreement • July 1st, 2025 • Curanex Pharmaceuticals Inc • Pharmaceutical preparations • New York
Curanex Pharmaceuticals Inc, a corporation incorporated under the law of the State of Nevada (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Pacific Century Securities, LLC, acting as the representative (the “Representative”) of the underwriters named on Schedule I hereto. (each an “Underwriter” and together, the “Underwriters”) an aggregate of [*] shares (the “Closing Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). No Closing Shares will be certificated. At the option of the Underwriters, the Company agrees, subject to the terms and conditions herein, to issue and sell additional Option Shares (as defined in Section 3(b) hereof). The Closing Shares and the Option Shares are herein referred to collectively as the “Securities.” The number of Closing Shares and Option Shares to be purchased by each Underwriter is set forth opposite its name in Schedule I hereto. Each of the Underwriter
UNDERWRITING AGREEMENT June 17, 2025Underwriting Agreement • June 18th, 2025 • Stardust Power Inc. • Primary smelting & refining of nonferrous metals • New York
Stardust Power Inc., a Delaware corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of 21,500,000 of the Company’s shares of Common Stock, $0.0001 par value per share (“Common Stock”; such 21,500,000 offered shares of Common Stock the “Closing Shares”). At the option of the Underwriter, the Company agrees, subject to the terms and conditions herein, to issue and sell up to an aggregate of 3,225,000 additional shares of Common Stock representing fifteen percent (15.0%) of the Closing Shares sold in the offering (the “Option Shares”). The Closing Shares and the Option Shares are herein referred to collectively as the “Shares”. The number of Shares to be purchased by the Underwriter is set forth opposite its name in Schedule 4.1.2 hereto. Aegis Capital Corp. has agreed to act as the Underwriter in connection with the offering and sale of the Securities.
UNDERWRITING AGREEMENTUnderwriting Agreement • June 18th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • June 11th, 2025 • Stardust Power Inc. • Primary smelting & refining of nonferrous metals • New York